Reuters: Global Markets: Ziopharm cancer drug fails in late-stage trial; shares plunge

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Ziopharm cancer drug fails in late-stage trial; shares plunge Mar 26th 2013, 11:24 Tue Mar 26, 2013 7:24am EDT (Reuters) - Ziopharm Oncology Inc said a late-stage trial of its cancer drug failed to meet the main goal of improving patients' survival without the cancer worsening, and the company decided to stop developing the treatment. The company's shares were down 58 percent at $2.15 in premarket trading on Tuesday. An independent committee recommended that patients be followed to test the improvement in their overall survival, but Ziopharm said it does not expect to continue the follow-up. The drug, palifosfamide, was being tested as a treatment for metastatic soft tissue sarcoma - a type of cancer of the bone, cartilage, fat or muscles.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions